Adnexus Therapeutics, Inc.: Considering the Exit Harvard Case Solution & Analysis

Dr. John Mendlein, the CEO of Adnexus Therapeutics Inc., (Adnexus), a privately held biotechnology company, must resolve whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six month cooperation or continue with Adnexus' planned IPO.

PUBLICATION DATE: November 11, 2008 PRODUCT #: 609015-PDF-ENG

This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.